Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
VELTIN™
(clindamycin phosphate and tretinoin) Gel
VELTIN™ (clindamycin phosphate and tretinoin) Gel, 1.2%/0.025%, is a fixed combination of two solubilized active ingredients in an aqueous based gel. Clindamycin phosphate is a water soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin.
The chemical name for clindamycin phosphate is methyl 7-chloro-6,7,8-trideoxy-6-(l-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside 2-(dihydrogen phosphate). The structural formula for clindamycin phosphate is represented below:
Clindamycin phosphate:
 |
VELTIN (clindamycin phosphate and tretinoin gel) Gel contains the following inactive ingredients: butylated hydroxytoluene, carbomer 940, anhydrous citric acid, edetate disodium, methylparaben, laureth 4, propylene glycol, tromethamine, and purified water.
VELTIN™ (clindamycin phosphate and tretinoin) Gel, 1.2%/0.025% is indicated for the topical treatment of acne vulgaris in patients 12 years or older.
VELTIN (clindamycin phosphate and tretinoin gel) Gel should be applied once daily in the evening, gently rubbing the medication to lightly cover the entire affected area. Approximately a pea sized amount will be needed for each application. Avoid the eyes, lips, and mucous membranes.
VELTTN Gel is not for oral, ophthalmic, or intravaginal use.
VELTIN (clindamycin phosphate and tretinoin gel) Gel, containing clindamycin phosphate 1.2% and tretinoin 0.025%, is a yellow, opaque topical gel. Each gram of VELTIN (clindamycin phosphate and tretinoin gel) Gel contains, as dispensed, 10 mg (1%) clindamycin as clindamycin phosphate, and 0.25 mg (0.025%) tretinoin solubilized in an aqueous based gel.
VELTIN (clindamycin phosphate and tretinoin gel) Gel is supplied as follows:
30 g aluminum tubes...................NDC 0145-0071-30
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).
Manufactured for: Stiefel Laboratories, Inc. Research Triangle Park, NC 27709. Manufactured by: DPT Laboratories, Ltd. 307 E. Josephine Street San Antonio, TX 78215. Revised: 07/2010
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.
The safety data reflect exposure to VELTIN (clindamycin phosphate and tretinoin gel) Gel in 1,104 patients with acne vulgaris. Patients were 12 years or older and were treated once daily in the evening for 12 weeks. Adverse reactions that were reported in ≥ 1% of patients treated with VELTIN (clindamycin phosphate and tretinoin gel) Gel are presented in Table 1.
Table 1: Treatment-Related Adverse Reactions Reported by
≥ 1% of Subjects
| VELTIN (clindamycin phosphate and tretinoin gel) Gel N=1104 n (%) |
ClindamycinGel N=1091 n (%) |
TretinoinGel N=1084 n(%) |
VehicleGel N=552 n (%) |
|
| Patients with at least one adverse reaction | 140(13) | 38(3) | 141 (13) | 17(3) |
| Application site dryness | 64(6) | 12(1) | 62(6) | 3(1) |
| Application site irritation | 50(5) | 4( < 1) | 57(5) | 5(1) |
| Application site exfoliation | 50(5) | 2( < 1) | 56(5) | 2( < 1) |
| Application site erythema | 40(4) | 6(1) | 39(4) | 3(1) |
| Application site pruritus | 26(2) | 7(1) | 23(2) | 6(1) |
| Sunburn | 11(1) | 6(1) | 7(1) | 3(1) |
| Application site dermatitis | 6(1) | 0(0) | 8(1) | 1( < 1) |
Local skin reactions actively assessed at baseline and end of treatment with a score > 0 are presented in Table 2.
Table 2: VELTIN (clindamycin phosphate and tretinoin gel) GEL-Treated Patients with Local Skin Reactions
| VELTIN GEL | VEHICLE GEL | |||
| Local Reaction | Baseline N=476 N(%) |
End of Treatment N=409 N(%) |
Baseline N=219 N(%) |
End of Treatment N=209 N(%) |
| Erythema | 24% | 21% | 31% | 35% |
| Scaling | 8% | 19% | 14% | 12% |
| Dryness | 11% | 22% | 18% | 13% |
| Burning | 8% | 13% | 8% | 4% |
| Itching | 17% | 15% | 22% | 14% |
During the twelve weeks of treatment, each local skin reaction peaked at week 2 and gradually reduced thereafter.
VELTIN™ (clindamycin phosphate and tretinoin gel) Gel should not be used in combination with erythromycin-containing products due to possible antagonism to the clindamycin component. In vitro studies have shown antagonism between these 2 antimicrobials. The clinical significance of this in vitro antagonism is not known.
Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, VELTIN (clindamycin phosphate and tretinoin gel) Gel should be used with caution in patients receiving such agents.
Included as part of the PRECAUTIONS section.
Systemic absorption of clindamycin has been demonstrated following topical use. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical clindamycin. If significant diarrhea occurs, VELTIN™ (clindamycin phosphate and tretinoin gel) Gel should be discontinued.
Severe colitis has occurred following oral orparenteral administration of clindamycin with an onset of up to several weeks following cessation of therapy. Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen severe colitis. Severe colitis may result in death.
Studies indicate a toxin(s) produced by clostridia is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Stool cultures for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically.
Exposure to sunlight, including sunlamps, should be avoided during the use of VELTIN (clindamycin phosphate and tretinoin gel) Gel, and patients with sunburn should be advised not to use the product until fully recovered because of heightened susceptibility to sunlight as a result of the use of tretinoin. Patients who may be required to have considerable sun exposure due to occupation and those with inherent sensitivity to the sun should exercise particular caution. Daily use of sunscreen products and protective apparel (e.g., a hat) are recommended. Weather extremes, such as wind or cold, also may be irritating to patients under treatment with VELTIN (clindamycin phosphate and tretinoin gel) Gel.
[See FDA-approved Patient Labeling].
VELTIN (clindamycin phosphate and tretinoin gel) Gel may cause irritation such as erythema, scaling, itching, burning, or stinging.
In the event a patient treated with VELTIN (clindamycin phosphate and tretinoin gel) Gel experiences severe diarrhea or gastrointestinal discomfort, VELTIN (clindamycin phosphate and tretinoin gel) Gel should be discontinued and a physician should be contacted.
Long-term animal studies have not been performed to evaluate the carcinogenic potential of VELTIN (clindamycin phosphate and tretinoin gel) Gel or the effect of VELTIN (clindamycin phosphate and tretinoin gel) Gel on fertility. VELTIN (clindamycin phosphate and tretinoin gel) Gel was negative for mutagenic potential when evaluated in an in vitro Ames Salmonella reversion assay. VELTIN (clindamycin phosphate and tretinoin gel) Gel was equivocal for clastogenic potential in the absence of metabolic activation when tested in an in vitro chromosomal aberration assay.
Once daily dermal administration of 1% clindamycin as clindamycin phosphate in the VELTIN (clindamycin phosphate and tretinoin gel) Gel vehicle (32 mg/kg/day, 13 times the recommended clinical dose based on body surface area comparison) to mice for up to 2 years did not produce evidence of tumorigenicity.
Fertility studies in rats treated orally with up to 300 mg/kg/day of clindamycin (240 times the recommended clinical dose based on body surface area comparison) revealed no effects on fertility or mating ability.
In two independent mouse studies where tretinoin was administered topically (0.025% or 0.1%) three times per week for up to two years no carcinogenicity was observed, with maximum effects of dermal amyloidosis. However, in a dermal carcinogenicity study in mice, tretinoin applied at a dose of 5.1 ug (1.4 times the recommended clinical dose based on body surface area comparison) three times per week for 20 weeks acted as a weak promoter of skin tumor formation following a single application of dimethylbenz[a]anthracene (DMBA).
In a study in female SENCAR mice, papillomas were induced by topical exposure to DMBA followed by promotion with 12-O-tetradecanoyl-phorbol 13-acetate or mezerein for up to 20 weeks. Topical application of tretinoin prior to each application of promoting agent resulted in a reduction in the number of papillomas per mouse. However, papillomas resistant to topical tretinoin suppression were at higher risk for pre-malignant progression.
Tretinoin has been shown to enhance photoco-carcinogenicity in properly performed specific studies, employing concurrent or intercurrent exposure to tretinoin and UV radiation. The photoco-carcinogenic potential of the clindamycin tretinoin combination is unknown. Although the significance of these studies to humans is not clear, patients should avoid exposure to sun.
The genotoxic potential of tretinoin was evaluated in an in vitro Ames Salmonella reversion test and an in vitro chromosomal aberration assay in Chinese hamster ovary cells. Both tests were negative.
In oral fertility studies in rats treated with tretinoin, the no-observed-effect-level was 2 mg/kg/day (64 times the recommended clinical dose based on body surface area comparison).
Pregnancy Category C. There are no well-controlled studies in pregnant women treated with VELTIN (clindamycin phosphate and tretinoin gel) Gel. VELTIN (clindamycin phosphate and tretinoin gel) Gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. A limit teratology study performed in Sprague Dawley rats treated topically with VELTIN (clindamycin phosphate and tretinoin gel) Gel or 0.025% tretinoin gel at a dose of 2 mL/kg during gestation days 6 to 15 did not result in teratogenic effects. Although no systemic levels of tretinoin were detected, craniofacial and heart abnormalities were described in drug-treated groups. These abnormalities are consistent with retinoid effects and occurred at 16 times the recommended clinical dose assuming 100% absorption and based on body surface area comparison. For purposes of comparison of the animal exposure to human exposure, the recommended clinical dose is defined as 1 g of VELTIN (clindamycin phosphate and tretinoin gel) Gel applied daily to a 50 kg person.
Reproductive developmental toxicity studies performed in rats and mice using oral doses of clindamycin up to 600 mg/kg/day (480 and 240 times the recommended clinical dose based on body surface area comparison, respectively) or subcutaneous doses of clindamycin up to 180 mg/kg/day (140 and 70 times the recommended clinical dose based on body surface area comparison, respectively) revealed no evidence of teratogenicity.
Oral tretinoin has been shown to be teratogenic in mice, rats, hamsters, rabbits, and primates. It was teratogenic and fetotoxic in Wistar rats when given orally at doses greater than 1 mg/kg/day (32 times the recommended clinical dose based on body surface area comparison). However, variations in teratogenic doses among various strains of rats have been reported. In the cynomologous monkey, a species in which tretinoin metabolism is closer to humans than in other species examined, fetal malformations were reported at oral doses of 10 mg/kg/day or greater, but none were observed at 5 mg/kg/day (324 times the recommended clinical dose based on body surface area comparison), although increased skeletal variations were observed at all doses. Dose-related teratogenic effects and increased abortion rates were reported in pigtail macaques.
With widespread use of any drug, a small number of birth defect reports associated temporally with the administration of the drug would be expected by chance alone. Thirty cases of temporally associated congenital malformations have been reported during two decades of clinical use of another formulation of topical tretinoin. Although no definite pattern of teratogenicity and no causal association have been established from these cases, 5 of the reports describe the rare birth defect category, holoprosencephaly (defects associated with incomplete midline development of the forebrain). The significance of these spontaneous reports in terms of risk to fetus is not known.
It is not known whether clindamycin is excreted in human milk following use of VELTIN (clindamycin phosphate and tretinoin gel) Gel. However, orally and parenterally administered clindamycin has been reported to appear in breast milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. It is not known whether tretinoin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when VELTIN (clindamycin phosphate and tretinoin gel) Gel is administered to a nursing woman.
Safety and effectiveness of VELTIN (clindamycin phosphate and tretinoin gel) Gel in pediatric patients below the age of 12 years have not been established.
Clinical trials of VELTIN (clindamycin phosphate and tretinoin gel) Gel included 2,086 patients 12-17 years of age with acne vulgaris. [See Clinical Studies]
Clinical studies of VELTIN (clindamycin phosphate and tretinoin gel) Gel did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
No information provided.
VELTIN (clindamycin phosphate and tretinoin gel) Gel is contraindicated in patients with regional enteritis, ulcerative colitis, or history of antibiotic-associated colitis.
[See Microbiology]
Although the exact mode of action of tretinoin is unknown, current evidence suggests that topical tretinoin decreases cohesiveness of follicular epithelial cells with decreased microcomedone formation. Additionally, tretinoin stimulates mitotic activity and increased turnover of follicular epithelial cells causing extrusion of the comedones.
In an open-label study of 17 patients with moderate-to-severe acne vulgaris, topical administration of approximately 3 grams of VELTIN (clindamycin phosphate and tretinoin gel) Gel once daily for 5 days, clindamycin concentrations were quantifiable in all 17 patients starting from 1 hour post dose. All plasma clindamycin concentrations were ≤ 5.56 ng/mL on day 5, with the exception of one subject who had a maximum clindamycin concentration of 8.73 ng/mL at 4 hours post-dose. There was no appreciable increase in systemic exposure to tretinoin, as compared to the baseline value. The average tretinoin concentration across all sampling times on day 5 ranged from 1.19 to 1.23 ng/mL compared with the corresponding baseline mean tretinoin concentration range of 1.16 to 1.30 ng/mL.
No microbiology studies were conducted in the clinical trials with this product.
Clindamycin binds to the SOS ribosomal subunit of susceptible bacteria and prevents elongation of peptide chains by interfering with peptidyl transfer, thereby suppressing protein synthesis. Clindamycin has been shown to have in vitro activity against Propionibacterium acnes (P. acnes), an organism that has been associated with acne vulgaris; however, the clinical significance of this activity against P. acnes was not examined in clinical studies with VELTIN™ (clindamycin phosphate and tretinoin gel) Gel. P. acnes resistance to clindamycin has been documented.
The treatment of acne with antimicrobials is associated with the development of antimicrobial resistance in P. acnes as well as other bacteria (e.g. Staphylococcus aureus, Streptococcus pyogenes). The use of clindamycin may result in developing inducible resistance in these organisms. This resistance is not detected by routine susceptibility testing.
Resistance to clindamycin is often associated with resistance to erythromycin.
The safety and efficacy of VELTIN (clindamycin phosphate and tretinoin gel) Gel, applied once daily for the treatment of acne vulgaris, was evaluated in 12-week multicenter, randomized, blinded studies in subjects 12 years and older.
Treatment response was defined as the percent of subjects who had a two grade improvement from baseline to Week 12 based on the Investigator's Global Assessment (IGA) and a mean absolute change from baseline to Week 12 in two out of three (total, inflammatory and non-inflammatory) lesion counts. The IGA scoring scale used in all the clinical trials for VELTIN (clindamycin phosphate and tretinoin gel) Gel is as follows:
| 0 | Clear | Normal, clear skin with no evidence of acne vulgaris. |
| 1 | Almost Clear | Skin almost clear; rare non-inflammatory lesions present, with rare non-inflamed papules (papules must be resolving and may be nyperpigmented, though not pink-red) requiring no further treatment in the Investigator's opinion. |
| 2 | Mild | Some non-inflammatory lesions are present, with few inflammatory lesions (papules/pustules only, no nodulo-cystic lesions). |
| 3 | Moderate | Non-inflammatory lesions predominate, with multiple inflammatory lesions evident; several to many comedones and papules/pustules, and there may or may not be 1 small nodulo-cystic lesion. |
| 4 | Severe | Inflammatory lesions are more apparent; many comedones and papules/pustules, there may or may not be a few nodulo-cystic lesions. |
| 5 | Very Severe | Highly inflammatory lesions predominate; variable numbers of comedones, many papules/pustules and nodulo-cystic lesions. |
In Study 1, 1649 subjects were randomized to VELTIN (clindamycin phosphate and tretinoin gel) Gel, Clindamycin gel, Tretinoin gel, and vehicle gel. The median age of subjects was 17 years old and 58% were females. At baseline, subjects had an average of 71 total lesions of which the mean number of inflammatory lesions was 25.5 lesions and the mean number of non-inflammatory lesions was 45.1 lesions. The majority of subjects enrolled with a baseline IGA score of 3. The efficacy results at week 12 are presented in Table 3.
Table 3: Efficacy Results at Week 12
| Study 1 | VELTIN Gel N=476 |
Clindamycin Gel N=467 |
Tretinoin Gel N=464 |
Vehicle Gel N=242 |
| Investigator's Global Assessment | ||||
| Percentage of subjects achieving Two Grade Improvement | 36.3% | 26.6% | 26.1% | 20.2% |
| Percentage of subjects achieving an IGA of 0 or 1 with a Two Grade Improvement | 33.2% | 24.0% | 22.6% | 17.8% |
| Inflammatory Lesions: | ||||
| Mean absolute reduction | 15.5 | 14.5 | 13.9 | 11.1 |
| Mean percentage (%) reduction | 60.4% | 56.5% | 54.5% | 43.3% |
| Non-inflammatory Lesions: | ||||
| Mean absolute reduction | 23.2 | 19.5 | 22.1 | 17.0 |
| Mean percentage (%) reduction | 51.0% | 42.9% | 47.3% | 36.0% |
| Total Lesions: | ||||
| Mean absolute reduction | 38.7 | 34.0 | 36.0 | 28.1 |
| Mean percentage (%) reduction | 55.0% | 49.0% | 50.5% | 39.1% |
The safety and efficacy of clindamycin-tretinoin gel was also evaluated in two additional 12-week, multi-centered, randomized, blinded, studies in patients 12 years and older. A total of 2219 subjects with mild-to-moderate acne vulgaris were treated once daily for 12 weeks. Of the 2219 subjects, 634 subjects were treated with clindamycin-tretinoin gel. These studies demonstrated consistent outcomes.
VELTIN
(vel-tin)
(clindamycin phosphate and tretinoin) Gel
IMPORTANT: For use on skin only (topical use). Do not get VELTIN (clindamycin phosphate and tretinoin gel) Gel in your mouth, eyes, or vagina.
Read the Patient Information that comes with VELTIN (clindamycin phosphate and tretinoin gel) Gel before you start using it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your medical condition or your treatment.
What is VELTIN Gel?
VELTIN™ (clindamycin phosphate and tretinoin gel) Gel is prescription medicine used on the skin to treat acne in people 12 years and older.
It is not known if VELTIN (clindamycin phosphate and tretinoin gel) Gel is safe and effective in children under 12 years of age.
Who should not use VELTIN (clindamycin phosphate and tretinoin gel) Gel?
Do not use VELTIN (clindamycin phosphate and tretinoin gel) Gel if you have:
Talk to your doctor if you are not sure if you have one of these conditions.
What should I tell my doctor before using VELTIN (clindamycin phosphate and tretinoin gel) Gel?
Before using VELTIN (clindamycin phosphate and tretinoin gel) Gel, tell your doctor if you:
Tell your doctor about all the medicines and skin products you use. Especially tell your doctor if you take medicine that contains erythromycin. VELTIN (clindamycin phosphate and tretinoin gel) Gel should not be used with products that contain erythromycin.
Know the medicines you take. Keep a list of your medicines and show it to your doctor and pharmacist when you get a new medicine.
How should I use VELTIN Gel?
Instructions for applying VELTIN (clindamycin phosphate and tretinoin gel) Gel:
What should I avoid while using VELTIN (clindamycin phosphate and tretinoin gel) Gel?
What are the possible side effects of VELTIN (clindamycin phosphate and tretinoin gel) Gel?
VELTIN (clindamycin phosphate and tretinoin gel) Gel may cause serious side effects, including:
Common side effects of VELTIN (clindamycin phosphate and tretinoin gel) Gel include:
Talk to your doctor about any side effect that bothers you or that does not go away.
These are not all the side effects with VELTIN (clindamycin phosphate and tretinoin gel) Gel. Ask your doctor or pharmacist for more information.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store VELTIN (clindamycin phosphate and tretinoin gel) Gel?
General information about VELTIN™ (clindamycin phosphate and tretinoin gel) Gel
Medicines are sometimes prescribed for purposes other than those listed in the patient information leaflet. Do not use VELTIN™ (clindamycin phosphate and tretinoin gel) Gel for a condition for which it was not prescribed. Do not give VELTIN™ (clindamycin phosphate and tretinoin gel) Gel to other people, even if they have the same symptoms you have. It may harm them.
This patient information leaflet summarizes the most important information about VELTIN™ (clindamycin phosphate and tretinoin gel) Gel. If you would like more information, talk with your doctor. You can also ask your pharmacist or doctor for information about VELTIN™ (clindamycin phosphate and tretinoin gel) Gel that is written for healthcare professionals. For more information call 1-888-784-3335.
What are the ingredients in VELTIN™ Gel?
Active Ingredients: clindamycin phosphate and tretinoin
Inactive Ingredients: butylated hydroxytoluene, carbomer 940, citric acid anhydrous, edetate disodium, methylparaben, laureth 4, propylene glycol, tromethamine, and purified water.
